Treatment of Venous Thromboembolism

Roderick Nazario, Lawrence J. Dclorenzo, George P. Maguire, Jay B. Dobkin, Joseph Reichel

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Venous thromboembolism (VTE) is a disease entity composed of pulmonary embolism (PE) and deep vein thrombosis (DVT). Anticoagulation, initiated as soon as the diagnosis is suspected, is the treatment of choice. Traditionally, anticoagulation is started with intravenous heparin, and changed to warfarin for long-term treatment. The introduction of unmonitored, subcutaneously administered, low molecular weight heparin has resulted in shorter hospitalizations, reduced the incidence of major bleeding as a complication, and shifted the treatment of VTE for selected patients to the outpatient setting. Thrombolytic therapy has been recommended for patients with life-threatening PE. Technologic advances in catheter embolectomy and fragmentation permit clot resolution in patients in whom thrombolytic therapy is contraindicated. Inferior cava filters can be placed percutaneously in patients at high risk for VTE or those in whom anticoagulation is contraindicated. Because VTE is often clinically silent, prevention of VTE is therefore the most effective means to reduce associated morbidity and mortality. Strategies to prevent VTE have been studied and validated for specific clinical circumstances.

Original languageEnglish (US)
Pages (from-to)438-445
Number of pages8
JournalHeart Disease
Volume2
Issue number6
StatePublished - Nov 2000

Fingerprint

Venous Thromboembolism
Thrombolytic Therapy
Pulmonary Embolism
Therapeutics
Embolectomy
Low Molecular Weight Heparin
Warfarin
Venous Thrombosis
Heparin
Hospitalization
Outpatients
Catheters
Hemorrhage
Morbidity
Mortality
Incidence

Keywords

  • Heparin
  • Inferior vena cava filter
  • Low molecular weight heparin
  • Pulmonary embolism
  • Venous thromboembolism
  • Warfarin

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Nazario, R., Dclorenzo, L. J., Maguire, G. P., Dobkin, J. B., & Reichel, J. (2000). Treatment of Venous Thromboembolism. Heart Disease, 2(6), 438-445.

Treatment of Venous Thromboembolism. / Nazario, Roderick; Dclorenzo, Lawrence J.; Maguire, George P.; Dobkin, Jay B.; Reichel, Joseph.

In: Heart Disease, Vol. 2, No. 6, 11.2000, p. 438-445.

Research output: Contribution to journalArticle

Nazario, R, Dclorenzo, LJ, Maguire, GP, Dobkin, JB & Reichel, J 2000, 'Treatment of Venous Thromboembolism', Heart Disease, vol. 2, no. 6, pp. 438-445.
Nazario R, Dclorenzo LJ, Maguire GP, Dobkin JB, Reichel J. Treatment of Venous Thromboembolism. Heart Disease. 2000 Nov;2(6):438-445.
Nazario, Roderick ; Dclorenzo, Lawrence J. ; Maguire, George P. ; Dobkin, Jay B. ; Reichel, Joseph. / Treatment of Venous Thromboembolism. In: Heart Disease. 2000 ; Vol. 2, No. 6. pp. 438-445.
@article{10240904394145609acb22a42238f5eb,
title = "Treatment of Venous Thromboembolism",
abstract = "Venous thromboembolism (VTE) is a disease entity composed of pulmonary embolism (PE) and deep vein thrombosis (DVT). Anticoagulation, initiated as soon as the diagnosis is suspected, is the treatment of choice. Traditionally, anticoagulation is started with intravenous heparin, and changed to warfarin for long-term treatment. The introduction of unmonitored, subcutaneously administered, low molecular weight heparin has resulted in shorter hospitalizations, reduced the incidence of major bleeding as a complication, and shifted the treatment of VTE for selected patients to the outpatient setting. Thrombolytic therapy has been recommended for patients with life-threatening PE. Technologic advances in catheter embolectomy and fragmentation permit clot resolution in patients in whom thrombolytic therapy is contraindicated. Inferior cava filters can be placed percutaneously in patients at high risk for VTE or those in whom anticoagulation is contraindicated. Because VTE is often clinically silent, prevention of VTE is therefore the most effective means to reduce associated morbidity and mortality. Strategies to prevent VTE have been studied and validated for specific clinical circumstances.",
keywords = "Heparin, Inferior vena cava filter, Low molecular weight heparin, Pulmonary embolism, Venous thromboembolism, Warfarin",
author = "Roderick Nazario and Dclorenzo, {Lawrence J.} and Maguire, {George P.} and Dobkin, {Jay B.} and Joseph Reichel",
year = "2000",
month = "11",
language = "English (US)",
volume = "2",
pages = "438--445",
journal = "Heart Disease",
issn = "1521-737X",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Treatment of Venous Thromboembolism

AU - Nazario, Roderick

AU - Dclorenzo, Lawrence J.

AU - Maguire, George P.

AU - Dobkin, Jay B.

AU - Reichel, Joseph

PY - 2000/11

Y1 - 2000/11

N2 - Venous thromboembolism (VTE) is a disease entity composed of pulmonary embolism (PE) and deep vein thrombosis (DVT). Anticoagulation, initiated as soon as the diagnosis is suspected, is the treatment of choice. Traditionally, anticoagulation is started with intravenous heparin, and changed to warfarin for long-term treatment. The introduction of unmonitored, subcutaneously administered, low molecular weight heparin has resulted in shorter hospitalizations, reduced the incidence of major bleeding as a complication, and shifted the treatment of VTE for selected patients to the outpatient setting. Thrombolytic therapy has been recommended for patients with life-threatening PE. Technologic advances in catheter embolectomy and fragmentation permit clot resolution in patients in whom thrombolytic therapy is contraindicated. Inferior cava filters can be placed percutaneously in patients at high risk for VTE or those in whom anticoagulation is contraindicated. Because VTE is often clinically silent, prevention of VTE is therefore the most effective means to reduce associated morbidity and mortality. Strategies to prevent VTE have been studied and validated for specific clinical circumstances.

AB - Venous thromboembolism (VTE) is a disease entity composed of pulmonary embolism (PE) and deep vein thrombosis (DVT). Anticoagulation, initiated as soon as the diagnosis is suspected, is the treatment of choice. Traditionally, anticoagulation is started with intravenous heparin, and changed to warfarin for long-term treatment. The introduction of unmonitored, subcutaneously administered, low molecular weight heparin has resulted in shorter hospitalizations, reduced the incidence of major bleeding as a complication, and shifted the treatment of VTE for selected patients to the outpatient setting. Thrombolytic therapy has been recommended for patients with life-threatening PE. Technologic advances in catheter embolectomy and fragmentation permit clot resolution in patients in whom thrombolytic therapy is contraindicated. Inferior cava filters can be placed percutaneously in patients at high risk for VTE or those in whom anticoagulation is contraindicated. Because VTE is often clinically silent, prevention of VTE is therefore the most effective means to reduce associated morbidity and mortality. Strategies to prevent VTE have been studied and validated for specific clinical circumstances.

KW - Heparin

KW - Inferior vena cava filter

KW - Low molecular weight heparin

KW - Pulmonary embolism

KW - Venous thromboembolism

KW - Warfarin

UR - http://www.scopus.com/inward/record.url?scp=0034329566&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034329566&partnerID=8YFLogxK

M3 - Article

C2 - 11728295

AN - SCOPUS:0034329566

VL - 2

SP - 438

EP - 445

JO - Heart Disease

JF - Heart Disease

SN - 1521-737X

IS - 6

ER -